Memantine/donepezil

Last updated

Memantine/donepezil
Combination of
Memantine NMDA receptor antagonist
Donepezil Acetylcholinesterase inhibitor
Clinical data
Trade names Namzaric
AHFS/Drugs.com Micromedex Detailed Consumer Information
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine hydrochloride (it acts as an NMDA receptor antagonist, among various other types of targets like 5-HT3 receptor, Nicotinic acetylcholine receptor, and Sigma-1 receptor) and donepezil hydrochloride, which is an acetylcholinesterase inhibitor. [1] It is taken by mouth. [1]

Memantine/donepezil was approved for medical use in the United States in 2014. [3]

References

  1. 1 2 3 4 "Namzaric- memantine hydrochloride and donepezil hydrochloride capsule; Namzaric- memantine hydrochloride and donepezil hydrochloride kit". DailyMed. 22 January 2019. Archived from the original on 20 January 2022. Retrieved 22 December 2023.
  2. ↑ "Periodic safety update report single assessment donepezil / memantine". European Medicines Agency. 7 March 2024. Retrieved 2 May 2024.
  3. ↑ "Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules". U.S. Food and Drug Administration (FDA). 13 May 2015. Archived from the original on 22 December 2023. Retrieved 22 December 2023.

Further reading


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.